Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 40

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 40
---
 |

<div align='center'>25</div>

|                                                     | We also announced a successful pre-Biologics License Application (BLA) meeting for RGX-121, where we finalized details of our BLA with the FDA. Then in alignment with the FDA we completed filing of the first two sections of the rolling BLA for RGX-121.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Pipeline Prioritization and Corporate Restructuring | We successfully implemented and completed our strategic pipeline prioritization and corporate restructuring announced in late 2023, which was designed to prioritize the development of ABBV-RGX-314, RGX-202 and RGX-121, while seeking strategic alternatives for our other clinical stage programs.We achieved our stated goal of strategic alternatives for our other clinical stage product candidates. We completed out-licensing agreements for RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In January 2025, we announced a strategic partnership to develop and commercialize RGX-121 and RGX-111 for the treatment of MPS II and MPS I, respectively, in the United States and Asia.We achieved our corporate objective of targeted cost reductions in excess of $50.0 million in 2024 stemming from the corporate restructuring plan implemented in late 2023. |
| Corporate Development and Pipeline Advancement      | We successfully transitioned senior leadership roles with the internal elevation of a newly appointed CEO and new external hire of a CFO. Looking towards early portfolio plans, we continued to invest in our pre-clinical pipeline.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Financial Strength                                  | We ended 2024 with $244.9 million in cash, cash equivalents and marketable securities. In the first quarter of 2025, the Company announced a strategic partnership with Nippon Shinyaku to develop and commercialize RGX-121 and RGX-111, with a $110.0 million upfront payment received under the collaboration in March 2025.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div align='center'>26</div>

Compensation Philosophy and Objectives The rapidly growing gene therapy industry has created a competitive recruitment and retention market for strong talent. It is our goal to ensure that we have the most skilled, innovative and resourceful executives on our leadership team. We foster an environment at REGENXBIO that